analysts and calls -- ML | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
analysts and calls -- ML

An SI Board Since September 2002

Posts	SubjectMarks	Bans
238	19	0

Emcee: scaram(o)uche	Type: Moderated

Introduction Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
113	BIIB Biogen IDEC Inc. Update; Tysabri Approved; Strong Combo Data, But Awaiti	tom pope	-	11/24/2004
112	Theravance Inc Initiation Comment; Drugs for Large Markets with Downside Suppo	tom pope	-	11/16/2004
111	Forest labs and SEPR: Forest Labs (FRX) Maintain Neutral. Lowering 05E from $2.	tom pope	-	10/29/2004
110	BIIB, already posted on ELN thread, posting here for completeness: Biogen IDEC	tom pope	-	10/28/2004
109	BIIB, already posted on ELN thread, posting here for completeness: Biogen IDEC	tom pope	-	10/28/2004
108	CELG. I'm beginning to wonder whether Ende is still with ML. Seems to me I	tom pope	-	10/25/2004
107	TEVA, with a reference to Antegren: <i>Teva Pharmaceutical (TEVA) Reitera	tom pope	-	10/22/2004
106	AMGN <i>Amgen Inc (AMGN) Reiterate Buy and $67 PT. 3Q Results: Raising 04	tom pope	-	10/21/2004
105	Wait, there's another one: <i>MGI Pharma (MOGN) Reiterate Buy and $34	tom pope	-	10/15/2004
104	MOGN. Nice to see this, MOGN could use a few friends: <i>MGI Pharma (MOG	tom pope	-	10/15/2004
103	Pharma and o'seas profits. Set the roughly 30% difference against PFE's	tom pope	-	10/12/2004
102	This is a pretty good trick. A screed on Pfizer that makes no mention of its inv	tom pope	-	10/8/2004
101	DNA <i>Genentech Inc (DNA) 2004 EPS raised to $0.83 from $0.80, 2005 EPS	tom pope	-	10/7/2004
100	<i>PFE deserves a premium multiple to the group based on its leadership po	nigel bates	-	10/4/2004
99	MRK and PFE. Merrill does not think the COX-2's are dead: MRK Maintain Neut	tom pope	-	10/1/2004
98	EYET: Eyetech Pharmaceuticals Inc. Company Update; Macugen Could Produce Reve	tom pope	-	10/1/2004
97	ONXX Onyx Pharmaceuticals, Inc. Initiating Coverage With a Neutral Rating We	tom pope	-	8/10/2004
96	NPSP NPS Pharmaceuticals Inc. Company Update; Positive Near-Term Catalysts Sh	tom pope	-	8/5/2004
95	AMGN: Amgen Inc 2Q04 Results; Reports Strong 2Q04 Results; Product Sales Abov	tom pope	-	7/23/2004
94	BTW, the "today" referred to in Ende's note is yesterday, I think.	tom pope	-	6/9/2004
93	Ende is exercized about the denseness of some of his colleagues - bolding is End	tom pope	-	6/9/2004
92	BIIB (my bolding - just talking my Elan book) Biogen IDEC Inc. Update; Positi	tom pope	-	5/1/2004
91	Well, I believe that Ende was looking at the gain in market cap, and chose "	scaram(o)uche	-	4/26/2004
90	LOL, I hadn't caught that one.	tom pope	-	4/26/2004
89	20% is "low"? :-)	scaram(o)uche	-	4/26/2004

Go to reply# or date (mm/dd/yy):